UY30529A1 - Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones - Google Patents

Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones

Info

Publication number
UY30529A1
UY30529A1 UY30529A UY30529A UY30529A1 UY 30529 A1 UY30529 A1 UY 30529A1 UY 30529 A UY30529 A UY 30529A UY 30529 A UY30529 A UY 30529A UY 30529 A1 UY30529 A1 UY 30529A1
Authority
UY
Uruguay
Prior art keywords
compounds
quinolin
procedures
compositions
formula
Prior art date
Application number
UY30529A
Other languages
English (en)
Inventor
Antonio Guglietta
Albert Palomer
Jose Luis Falco
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of UY30529A1 publication Critical patent/UY30529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a nuevos compuestos de 1H-quinolin-4-ona de formula (I), donde R1, R2, R3, R4 y R5 tienen diferente significado, y las sales farmacéuticamente aceptables e hidratos de los mismos. Los compuestos de formula (I) son utiles en el tratamiento o prevencion de enfermedades asociadas a la modulacion de los receptores GABAa, ansiedad, epilepsia, trastornos del sueno que incluyen insomnio e inducir sedadion -hipnosis, anestesia, sueno y relajacion muscular. La invencion también se refiere al procedimiento de síntesis para la preparacion de dichos compuestos.
UY30529A 2006-08-10 2007-08-07 Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones UY30529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06118720A EP1886996A1 (en) 2006-08-10 2006-08-10 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions

Publications (1)

Publication Number Publication Date
UY30529A1 true UY30529A1 (es) 2008-02-29

Family

ID=37651083

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30529A UY30529A1 (es) 2006-08-10 2007-08-07 Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones

Country Status (13)

Country Link
US (1) US20100168099A1 (es)
EP (1) EP1886996A1 (es)
CN (1) CN101522630A (es)
AR (1) AR062295A1 (es)
AT (1) ATE512138T1 (es)
BR (1) BRPI0715817A2 (es)
CL (1) CL2007002324A1 (es)
DK (1) DK2064185T3 (es)
PT (1) PT2064185E (es)
RU (1) RU2009108361A (es)
SI (1) SI2064185T1 (es)
TW (1) TW200833665A (es)
UY (1) UY30529A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
TWI492943B (zh) * 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
JP5769504B2 (ja) * 2010-06-04 2015-08-26 大塚製薬株式会社 医薬
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
GB9621757D0 (en) * 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
ES2319176T3 (es) * 2002-05-14 2009-05-05 The Regents Of The University Of California Acidos quinolona-carboxilicos sustituidos, sus derivados, sitio de accion y uso de los mismos.

Also Published As

Publication number Publication date
EP1886996A1 (en) 2008-02-13
AR062295A1 (es) 2008-10-29
TW200833665A (en) 2008-08-16
ATE512138T1 (de) 2011-06-15
SI2064185T1 (sl) 2011-10-28
CL2007002324A1 (es) 2008-01-18
RU2009108361A (ru) 2010-09-20
PT2064185E (pt) 2011-09-12
CN101522630A (zh) 2009-09-02
BRPI0715817A2 (pt) 2014-12-23
DK2064185T3 (da) 2011-09-19
US20100168099A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
CU20110145A7 (es) Derivados de sulfonamida
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
UY28752A1 (es) Agentes terapeuticos
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
UY30529A1 (es) Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones
UY29618A1 (es) " pirazolo(1,5-a) pirimidinas halogenadas, métodos, usos, composiciones e intermedios"
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
UY30521A1 (es) Pirazolo[1,5-a] pirimidinas, procesos, usos y composiciones
DOP2009000121A (es) Analogos de pirazol como inhibidores selectivos de 5-lo
NO20090971L (no) 1H-quinolin-4-on forbindelser med affinitet for GABA-receptoren, fremgangsmater, anvendelser og sammensetninger
UY30066A1 (es) Hidrazidas del acido imidazo(1,2-a) piridin-3-il-acético, procesos, usos y composiciones
AR068978A1 (es) N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas
UY30249A1 (es) Imidazo (1,2-b) piridazinas, procesos, usos intermedios y composiciones
ATE393148T1 (de) Neue benzimidazolderivative und ihre pharmazeutische zusammensetzungen
UY28819A1 (es) Derivados de formamida para el tratamiento de enfermedades
CL2008003141A1 (es) Compuestos derivados de 1-(3-alcoxi-fenil)-pirrolidin-3-il-aminas aciladas con actividad en los receptores mt1 y mt2; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de alteraciones melatoninergicas tales como depresion, alteraciones de sueño, diabetes, parkinson y alzheimer.
UY29310A1 (es) Agentes terapéuticos
UY29311A1 (es) Agentes terapeuticos
GT200500056A (es) Compuestos utiles para el tratamiento de enfermedades
PA8627101A1 (es) Compuestos para el tratamiento de enfermedades
PA8626401A1 (es) Compuestos útiles para el tratamiento de enfermedades